

## **Update**

# Special Interest Groups (SIGs)

Statistics Leaders Meeting June 11, 2014 Basel



# SIG: Updates

### Change of Chairs SIGs:

- SIG Benefit Risk
  - New Chair: Alexander Schacht (Lilly, Germany)
  - Previous Chair: Ian Hirsch (AZ, US)
- SIG Biomarkers
  - New Chair: Athula Herath (MedImmune)
  - Previous Chair: Martin Jenkins (AZ, UK)



# SIG presentations

- Statistics Leaders Meeting 2014
  - SIG Integrated Data Analysis
  - SIG Pharmaco-Epidemiology
- EFSPI Newsletter

February Health Technology Assessment

– March Biomarkers

April Medical Devices

– May Toxicology



# SIG of the Month in 2014

#### SIG contribution to EFSPI Newsletter in 2014

|                                 |                       | 2014 EFSPI Newsletter Schedule with SIG input |          |       |          |     |      |      |        |           |         |          |          |
|---------------------------------|-----------------------|---|----------|-------|----------|-----|------|------|--------|-----------|---------|----------|----------|
| SIG                             | SIG Lead              | January                                       | February | March | April    | May | June | July | August | September | October | November | December |
| Modelling & Simulation          | Chris Campbell        | ·   | ·        |       | ·        | ,   |      | ·    |        | ·         |         | Х        |          |
| Health Technology<br>Assessment | Chrissie Fletcher     |   | ₹        |       |          |     |      |      |        |           |         |          |          |
| Epidemiology &<br>Safety        | George Quartey        |   |          |       |          |     | Х    |      |        |           |         |          |          |
| Benefit/Risk                    | Alexander Schacht     |   |          |       |          |     |      |      |        |           | Х       |          |          |
| Biomarkers                      | Athula Herath         |   |          | V     |          |     |      |      |        |           |         |          |          |
| Medical Devices                 | Roland Marion-Gallois |   |          |       | <b>V</b> |     |      |      |        |           |         |          |          |
| Toxicology                      | Gareth Thomas         |   |          |       |          | V   |      |      |        |           |         |          |          |
| Integrated Data<br>Analysis     | Byron Jones           |   |          |       |          |     |      |      |        | X         |         |          |          |

# SIGs at Stats Leaders Mtgs

| Core Topics Stats Mtg  | 2014                 | 2013                 | 2012          | 2011          | 2010          | Link to SIG              |
|--|----------------------|----------------------|---------------|---------------|---------------|--------------------------|
| New SIG: Integrated Data Analysis                              | intro+discuss        |                      |               |               |               | Integrated Data Analysis |
| SIG: Pharmaco-Epidemiology & Safety                            | present +<br>discuss |                      |               |               |               | Epidemiology & Safety    |
| Risk - Benefit   |                      | present +<br>discuss |               | update        | intro+discuss | Benefit-Risk             |
| Assessing Risk Benefit - Roadmap                               |                      | update               | intro+discuss |               |               | Benefit-Risk             |
| Model Based Drug Development                                   |                      |                      |               | intro+discuss |               | Modeling & Simulation    |
| Totality of Evidence - observational data                      |                      |                      |               | intro+discuss |               | Epidemiology & Safety    |
| Health Technology Assesment (CER)                              |                      |                      |               | update        | intro+discuss | HTA (CER)                |
| Comparative drug effects - Network meta-analyses               |                      |                      |               | intro+discuss |               | HTA (CER)                |
|  |                      |                      |               |               |               | Biomarkers               |
| Medical Devices  |                      | intro+discuss        |               |               |               | Medical Devices          |
|  |                      |                      |               |               |               | Toxicology               |
|  |                      |                      |               |               |               |                          |
|  |                      |                      |               |               |               | Professional             |
| EMA Clinical Trial Data Transparency                           |                      | intro+discuss        |               |               |               | Transparency             |
| Adaptive statisticians & the challenges beyond Clinical Trials |                      |                      | intro+discuss |               |               | Career Path              |
| Professional development                                       |                      |                      | paper         | update        | intro+discuss | Career Path              |
| accreditation  |                      |                      |               | intro+discuss |               | Accreditation            |



## SIG Medical Devices

#### Stats Leaders Mtg 2013 – request to EFSPI:

- Contribute to comments on upcoming regulatory guidelines changes
- Backing up SIG in promoting good scientific practice as in pharma

#### Follow-up:

- EFSPI supported SIG in sending a letter to EU Parliament asking for attention to introduce more profound statistical principles in upcoming regulatory framework changes than presently proposed
  - no answer yet from EU deputies
  - Some of SIGs concerns taken into account
  - Yet current regulatory thinking also different from some expectations
  - Role of EMA is not as direct than expected
  - Post-market device surveillance is re-inforced
  - Notified bodies (which are delivering the CE mark) will be less and better controlled.



## SIG Benefit Risk

- Stats Leaders Meeting 2013 :
  - SIG can use EFSPI/PSI website for posting of material to be kept under SIG's control such as Position Papers, Presentations, etc.
  - SIG free to investigate more wiki-like environments for triggering more feedback (but without control)
  - Encouraged to collaborate with QSPI (US analogy to EFSPI), but not let that hold up development blue print



## SIG B/R follow up

- SIG had EFSPI/PSI one day meeting in September 2014
  - http://www.efspi.org/index.php?p=EFSPI%20ACTIVITIES&fid=431
- Submission publication:
  - "Structured Benefit-risk assessment: A review of key publications and initiatives on frameworks and methodologies"
- Regular meetings in subgroups
- Involvement in PROTECT
- Collaboration with QSPI:
  - intent to publish a newsletter together with QSPI related to B-R topics
- More information on website:
  - http://www.psiweb.org/index.php?p=resources&fid=1517#
- Planned 2-days Training in 2015
  - SIG is looking for venue (1 large room, 2 break outs)
  - please let Alexander Schacht know: schacht\_alexander@lilly.com



## Recent SIG publications

### HTA SIG

- Adjusting overall survival for treatment switches: Commonly used methods and practical application, Watkins et al
- Utility values in health technology assessments: a statistician's perspective, Whately-Smith et al
- Subgroup Analyses in Cost-Effectiveness Analyses to Support Health Technology Assessments, Fletcher et al



# Meetings planned 2014

- SIG Biomarkers:
  - Biomarkers Hands-on-workshop/"Biomarker Hackathon"
  - Big Data in Biomarker Development
  - currently scheduled to be held in Cambridge (UK)
- SIG Toxicology
  - Workshop (October)
- SIG Modelling & Simulation
  - ? Meeting planned with EMA
- SIG HTA / EFSPI meeting on HTA: Sept 25, Berlin

SIG Update 10